FDA

The fda is the U.S. Food and Drug Administration, a regulatory body that shapes drug development and safety assessment, especially by promoting human-relevant New Approach Methodologies (NAMs) and model-informed drug development (MIDD). Its role is central in modernizing preclinical testing with organoid-based and other human-relevant systems, while also overseeing clinical translation in areas such as oncology. The agency has approved 14 antibody-drug conjugates (ADCs) for clinical cancer use, reflecting its influence on advanced therapeutic modalities. It is also cited as the source of approved circulating biomarkers used in high-depth plasma proteomics workflows. Overall, the FDA functions as a key decision-making authority linking regulatory standards, biomarker qualification, and therapeutic approval across drug discovery and clinical development.

Drug Development and Regulatory Modernization

  • The FDA is driving regulatory shifts toward human-relevant human intestinal organoids and other NAMs for drug discovery and safety assessment, emphasizing replacement or refinement of traditional preclinical models. (PMID:41766415)
  • A 2026 Advanced Science paper (PMID:41766415) highlighted the FDA’s role in integrating organoids into regulatory workflows for preclinical evaluation.
  • The agency actively promotes model informed drug development as a framework for lifecycle drug development and regulatory decision-making. (PMID:41832623)
  • A 2026 Current Reviews in Clinical and Experimental Pharmacology review (PMID:41832623) described MIDD as a regulatory strategy supported by the FDA across development stages.

Oncology and Therapeutic Approval

  • The FDA has approved 14 antibody drug conjugates for use in clinical oncology, underscoring its role in enabling targeted cancer therapeutics. (PMID:41855081)
  • A 2026 Physiological Reviews article (PMID:41855081) summarized ADC design and mechanisms of action in cancer treatment in the context of FDA approvals.
  • FDA approval status is a key benchmark for translating ADC platforms from mechanism-based design to clinical use. (PMID:41855081)

Biomarkers and Proteomics Workflows

  • The FDA is referenced as the source of approved circulating biomarkers incorporated into an orthogonal extraction workflow for high-depth plasma proteomics. (PMID:41944463)
  • A 2026 Analytical Methods study (PMID:41944463) used FDA-approved biomarker context to support metabolomic-compatible plasma profiling from low microliter-scale samples.
  • This linkage highlights the FDA’s influence on biomarker standardization and downstream assay design. (PMID:41944463)